ArticleBiomedical reports2026
Efficacy and safety of mesenchymal stem cells for cerebral infarction: A meta-analysis.
Article in Biomedical reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebral infarction is one of the leading causes of death in adults, impairing patients' quality of life and imposing a heavy burden on families. With current therapeutic approaches, functional recovery after cerebral infarction remains suboptimal. Mesenchymal stem cells (MSCs), due to their broad availability, low immunogenicity, and multipotent differentiation potential, have promise in the treatment of ischemic cerebral infarction. The present study aimed to evaluate the efficacy and safety of mesenchymal stem cells in the treatment of cerebral infarction. VIP Information, China National Knowledge Infrastructure, Wanfang Data, PubMed, Cochrane Library and Web of Science were systematically searched up to October 2024 using the search terms 'mesenchymal stem cells', 'cerebral infarction', and 'randomized controlled trials', which yielded 19 randomized controlled trials for meta-analysis. The efficacy of mesenchymal stem cells in the treatment of cerebral infarction was better than that of conventional treatment, and mesenchymal stem cell therapy decreased the neurological deficit score (National Institutes of Health Stroke Scale) and improved the motor function score (Fugl-Meyer Assessment) and functional independence score (Functional Independence Measure, FIM). Mesenchymal stem cells have a high safety profile in the treatment of patients with cerebral infarction. Most of the adverse effects reported were fever and headache, which resolved spontaneously or following treatment. Umbilical cord mesenchymal stem cells were more effective than bone marrow mesenchymal stem cells. There was no significant difference between transplantation methods. This may be due to the small number of included studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.